BACKGROUND:Recombinant DNA and modified vaccinia virus Ankara (rMVA) vaccines represent a promising approach to an HIV/AIDS vaccine. This Phase 1 clinical trial compared the safety and immunogenicity of a rMVA vaccine administered with and without DNA vaccine priming METHODS: GeoVax pGA2/JS7 DNA (D) and MVA/HIV62 (M) vaccines encode noninfectious virus-like particles. Intramuscular needle injections were used to deliver placebo, 2 doses of DNA followed by 2 doses of rMVA (DDMM), one dose of DNA followed by 2 doses of rMVA (DMM), or 3 doses of rMVA (MMM) to HIV-seronegative participants. RESULTS:Local and systemic symptoms were mild or moderate. Immune response rates for CD4 + and CD8 + T cells were highest in the DDMM group and lowest in the MMM group (77% vs 43% CD4 + and 42% vs 17% CD8 +). In contrast, response rates for Env binding and neutralizing Ab were highest in the MMM group. The DMM group had intermediate response rates. A 1/10th-dose DDMM regimen induced similar T cell but reduced Ab response rates compared with the full-dose DDMM. CONCLUSIONS:MVA62 was well tolerated and elicited different patterns of T cell and Ab responses when administered alone or in combination with the JS7 DNA vaccine.
RCT Entities:
BACKGROUND: Recombinant DNA and modified vaccinia virus Ankara (rMVA) vaccines represent a promising approach to an HIV/AIDS vaccine. This Phase 1 clinical trial compared the safety and immunogenicity of a rMVA vaccine administered with and without DNA vaccine priming METHODS: GeoVax pGA2/JS7 DNA (D) and MVA/HIV62 (M) vaccines encode noninfectious virus-like particles. Intramuscular needle injections were used to deliver placebo, 2 doses of DNA followed by 2 doses of rMVA (DDMM), one dose of DNA followed by 2 doses of rMVA (DMM), or 3 doses of rMVA (MMM) to HIV-seronegative participants. RESULTS: Local and systemic symptoms were mild or moderate. Immune response rates for CD4 + and CD8 + T cells were highest in the DDMM group and lowest in the MMM group (77% vs 43% CD4 + and 42% vs 17% CD8 +). In contrast, response rates for Env binding and neutralizing Ab were highest in the MMM group. The DMM group had intermediate response rates. A 1/10th-dose DDMM regimen induced similar T cell but reduced Ab response rates compared with the full-dose DDMM. CONCLUSIONS: MVA62 was well tolerated and elicited different patterns of T cell and Ab responses when administered alone or in combination with the JS7 DNA vaccine.
Authors: R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson Journal: Science Date: 2001-04-06 Impact factor: 47.728
Authors: James M Smith; Rama Rao Amara; David Campbell; Yan Xu; Milloni Patel; Sunita Sharma; Salvatore T Butera; Dennis L Ellenberger; Hong Yi; Lakshmi Chennareddi; James G Herndon; Linda S Wyatt; David Montefiori; Bernard Moss; Harold M McClure; Harriet L Robinson Journal: AIDS Res Hum Retroviruses Date: 2004-12 Impact factor: 2.205
Authors: Paul A Goepfert; Helen Horton; M Juliana McElrath; Sanjay Gurunathan; Guido Ferrari; Georgia D Tomaras; David C Montefiori; Mary Allen; Ya-Lin Chiu; Paul Spearman; Jonathan D Fuchs; Beryl A Koblin; William A Blattner; Sharon Frey; Michael C Keefer; Lindsey R Baden; Lawrence Corey Journal: J Infect Dis Date: 2005-08-31 Impact factor: 5.226
Authors: R Pal; D Venzon; N L Letvin; S Santra; D C Montefiori; N R Miller; E Tryniszewska; M G Lewis; T C VanCott; V Hirsch; R Woodward; A Gibson; M Grace; E Dobratz; P D Markham; Z Hel; J Nacsa; M Klein; J Tartaglia; G Franchini Journal: J Virol Date: 2002-01 Impact factor: 5.103
Authors: Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para Journal: J Infect Dis Date: 2005-01-27 Impact factor: 5.226
Authors: Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori Journal: J Virol Date: 2005-08 Impact factor: 5.103
Authors: Linda S Wyatt; Patricia L Earl; Jin Yan Liu; James M Smith; David C Montefiori; Harriet L Robinson; Bernard Moss Journal: AIDS Res Hum Retroviruses Date: 2004-06 Impact factor: 2.205
Authors: James M Smith; Rama Rao Amara; Harold M McClure; Milloni Patel; Sunita Sharma; Hong Yi; Lakshmi Chennareddi; James G Herndon; Salvatore T Butera; Walid Heneine; Dennis L Ellenberger; Bharat Parekh; Patricia L Earl; Linda S Wyatt; Bernard Moss; Harriet L Robinson Journal: AIDS Res Hum Retroviruses Date: 2004-06 Impact factor: 2.205
Authors: S Top; E Foulon; B Pignolet; M Deplanche; C Caubet; C Tasca; S Bertagnoli; G Meyer; G Foucras Journal: J Virol Date: 2011-08-10 Impact factor: 5.103
Authors: Greg Finak; Andrew McDavid; Pratip Chattopadhyay; Maria Dominguez; Steve De Rosa; Mario Roederer; Raphael Gottardo Journal: Biostatistics Date: 2013-07-24 Impact factor: 5.899
Authors: Oksana Penezina; Neil X Krueger; Isaac R Rodriguez-Chavez; Michael P Busch; John Hural; Jerome H Kim; Robert J O'Connell; Eric Hunter; Said Aboud; Keith Higgins; Victor Kovalenko; David Clapham; David Crane; Andrew E Levin Journal: Clin Vaccine Immunol Date: 2014-01-08
Authors: Paul A Goepfert; Marnie L Elizaga; Kelly Seaton; Georgia D Tomaras; David C Montefiori; Alicia Sato; John Hural; Stephen C DeRosa; Spyros A Kalams; M Juliana McElrath; Michael C Keefer; Lindsey R Baden; Javier R Lama; Jorge Sanchez; Mark J Mulligan; Susan P Buchbinder; Scott M Hammer; Beryl A Koblin; Michael Pensiero; Chris Butler; Bernard Moss; Harriet L Robinson Journal: J Infect Dis Date: 2014-01-07 Impact factor: 5.226
Authors: Pierre-Alexandre Bart; Yunda Huang; Shelly T Karuna; Samuel Chappuis; Julien Gaillard; Nidhi Kochar; Xiaoying Shen; Mary A Allen; Song Ding; John Hural; Hua-Xin Liao; Barton F Haynes; Barney S Graham; Peter B Gilbert; M Juliana McElrath; David C Montefiori; Georgia D Tomaras; Giuseppe Pantaleo; Nicole Frahm Journal: J Clin Invest Date: 2014-10-01 Impact factor: 14.808
Authors: Charlotta Nilsson; Karina Godoy-Ramirez; Bo Hejdeman; Andreas Bråve; Lindvi Gudmundsdotter; David Hallengärd; Jeffrey R Currier; Lindsay Wieczorek; Klara Hasselrot; Patricia L Earl; Victoria R Polonis; Mary A Marovich; Merlin L Robb; Eric Sandström; Britta Wahren; Gunnel Biberfeld Journal: AIDS Res Hum Retroviruses Date: 2013-11-15 Impact factor: 2.205
Authors: Smita S Iyer; Sailaja Gangadhara; Blandine Victor; Xiaoying Shen; Xuemin Chen; Rafiq Nabi; Sudhir P Kasturi; Michael J Sabula; Celia C Labranche; Pradeep B J Reddy; Georgia D Tomaras; David C Montefiori; Bernard Moss; Paul Spearman; Bali Pulendran; Pamela A Kozlowski; Rama Rao Amara Journal: J Virol Date: 2016-09-12 Impact factor: 5.103